Skip to main content

Table 3 Mixed relative treatment effects of composite adverse events and estimated glomerular filtration rate among urate lowering agents

From: Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials

eGFR; MD (95% CI)
Probenecid - - -
0.52
(0.08, 3.52)
Febuxostat -0.80
(-2.66, 1.05)
2.89
(0.69, 5.09)
0.42
(0.10, 1.73)
0.80
(0.23, 2.82)
Allopurinol 3.69
(1.31, 6.08)
0.68
(0.16, 2.84)
1.30
(0.28, 5.99)
1.63
(0.70, 3.79)
Placebo/no ULT
Adverse events; RR (95% CI)
  1. CI Confidence interval, eGFR Estimated glomerular filtration rates, MD Mean difference, RR Risk ratio, ULT Urate-lowering therapy agents
  2. Comparisons are read from left to right for both eGFR and adverse events. For example; allopurinol had higher adverse events with RR (95% CI) of 1.63 (0.70, 3.79) compared with placebo/no ULT, and higher eGFR with MD (95% CI) of 3.69 (1.31, 6.08) compared with placebo/no ULT
  3. Bold font indicates statistical significance